Consequences and determinants of adherence to antiretroviral medication: Results from Adult AIDS Clinical Trials Group protocol 370

Antiviral Therapy

Volumn 7, Issue 3, 2002, Pages 185-193

  Ickovics, Jeannette R ^a   Cameron, Ann ^a   Zackin, Robert ^b   Basset, Roland ^b   Chesney, Margaret ^c   Johnson, Victoria A ^d   Kuritzkes, Daniel R ^e  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CENTER FOR BIOSTATISTICS IN AIDS RESEARCH   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^e UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; DELAVIRDINE; INDINAVIR; LAMIVUDINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; VIRUS RNA; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; BEHAVIOR; CLINICAL FEATURE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DRUG EFFICACY; FATIGUE; FEMALE; FEVER; GASTROINTESTINAL SYMPTOM; HEADACHE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; INFLUENZA; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALAISE; MALE; MINORITY GROUP; MULTICENTER STUDY; NEUROPATHY; NONHUMAN; PAIN; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; SELF REPORT; SKIN DISEASE; SOCIAL PSYCHOLOGY; VIRUS TITRATION;

ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; FEMALE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HIV; HIV INFECTIONS; HUMANS; MALE; PATIENT COMPLIANCE; RNA, VIRAL; TIME FACTORS; TREATMENT FAILURE;

EID: 0036768055     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Gulick R, Mellors J, Havlir D, Eron J, Gonzalez C, McMahon D, Richman D, Valentine F, Jonas L, Meibohm A, Emini E and Chodakewitz J. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. New England Journal of Medicine 1997; 337:734-739.
2. Hammer S, Squires K, Hughes M, Grimes J, Demeter L, Currier J, Eron J, Feinberg J, Balfour HJ, Deyton L, Chodakewitz J and Fischl M. A controlled trial of two nucleoside analogs plus indinavir in persons with human immunodeficiency virus infections and CD4 cell counts of 200 per cubic millimeter or less. New England Journal of Medicine 1997; 337:725-733.
3. Montaner J, Reiss P, Cooper D, Vella S, Harris M, Conway B, Wainberg M, Smith M, Robinson P, Hall D, Myers M and Lange J. A randomized double-blind trial comparin combinations of nevaripine, didanosine, and zidovudine for HIV-infected patients: the INCAS trial. Journal of the American Medical Association 1998; 279:930-937.
4. Palella FJ, Delany K, Moorman A, Loveless M, Fuhrer J, Satten G, Aschman D and Holmberg S. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. New England Journal of Medicine 1998; 338:850-860.
5. Cameron D, Heath-Chiozzi M, Danner S, Cohen C, Kravcik S, Maurath C, Sun E, Henry D, Rode R, Potthoff A and Leonard J. Randomized placebo-controlled trial of ritonavir in advanced HIV-1 disease. Lancet 1998; 351:343-349.
6. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Morbidity and Mortality Weekly Report 1998; 47 (No. RR-5):Updated as the Living Document, 5 February 2001, on the HIV/AIDS Treatment Information Web Site: www.hivatis.org
7. Hirsch M, Conway B, D'Aquila R, Johnson V, Brun-Vezinet F, Clotet B, Demeter L, Hammer S, Jacobsen D, Kuritzkes D, Loveday C, Mellors J, Vella S and Richman D. Antiretroviral drug resistance testing in adults with HIV infection. Journal of the American Medical Association 1998; 279:1984-1991.
8. Knobel H, Carmona A, Grau S, Pedro-Botet J and Dies A. Adherence and effectiveness of highly active antiretroviral therapy. Archives of Internal Medicine 1998; 158:1953.
9. Paterson D, Swindells S, Mohr J, Brester M, Vergis E, Squire C, Wagener M and Singh N. Adherence to protease inhibitor therapy and outcomes in patients with HIV infections. Annals of Internal Medicine 2000; 133:21-30.
10. Walsh J, Hertogs K and Gazzard B. Viral drug resistance, adherence and pharmacokenetic indices in HIV-1 infected patients on successful and failing protease inhibitor based HAART. 40th Interscience Conference of Antimicrobial Agents and Chemotherapy. Toronto, Canada, 2000.
11. Deeks S, Smith M, Holodniy M and Kahn J. HIV-1 protease inhibitors: a review for clinicians. Journal of the American Medical Association 1997; 277:145-153.
12. Perrin L and Telenti A. HIV treatment failure. Science 1998; 280:1871-1873.
13. Valdez L, Lederman M, Woolley I, Walker CJ, Vernon LT, Hise A and Gripshover BM. Human immunodeficiency virus 1 protease inhibitors in clinical practice: predictors of virological outcome. Archives of Internal Medicine 1999; 159:1771-1776.
14. Gallant J and Block D. Adherence to antiretroviral regimens in HIV-infected patients: results of a survey among physicians and patients. Journal of the International Association of Physicians for AIDS Care 1998; 4:32-35.
15. Kleeberger CA, Phair JP, Strathdee SA, Detels R, Kingsley L and Jacobson LP. Determinants of heterogeneous adherence to HIV-antiretroviral therapies in the multicenter AIDS cohort study. Journal of Acquired Immune Deficiency Syndrome 2001; 26:82-92.
16. Eldred L, Wu A, Chaisson R and Moore R. Adherence to antiretroviral and pneumocystis prophylaxis in HIV disease. Journal of Acquired Immune Deficiency Syndrome and Human Retrovirology 1998; 18:117-125.
17. Weidle P, Ganea C, Irwin K, McGowan J, Ernst J, Olivio N and Holmberg S. Adherence to antiretroviral medications in an inner-city population. Journal of Aquired Immune Deficiency Syndrome 1999; 22:498-502.
18. Catz SL, Kelly JA, Bogart LM, Benotsch EG and McAuliffe TL. Patterns, correlates and barriers to medication adherence among persons prescribed new treatments for HIV disease. Health Psychology 2000; 19:124-133.
19. Maher K, Klimas N, Fletcher M, Cohen V, Maggio C, Triplett J, Valenzuela R and Dickinson G. Disease progression, adherence, and response to protease inhibitor therapy for HIV infection in an urban veterans affairs medical center. Journal of Acquired Immune Deficiency Syndrome 1999; 22:358-363.
20. Hecht F, Colfax G, Swanson M and Chesney M. Adherence and effectiveness of protease inhibitors in clinical practice. Fifth Conference on Retroviruses and Opportunistic Infections. Chicago, Ill., USA 2-6 February 1998.
21. Condra J, Schleif W, Blahy O, Gabryelski L, Graham D, Quintero J, Rhodes A, Robbins H, Roth E, Shivaprakash M, Titus D, Yang T, Hedy, Teppler S, Deutsch P and Emini E. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 1995; 374:569-571.
22. Jacobsen H, Hanggi M, Ott M, Duncan I, Owen S, Andreoni M, Vella S and Mous J. In vivo resistance to an HIV-1 protease inhibitor: mutations, kinetics and frequencies. Journal of Infectious Diseases 1996; 173:1379-1387.
23. Roberts N. Drug resistance patterns of saquinavir and other protease inhibitors. AIDS 1995; 9(Suppl):S27-S32.
24. Max B and Sherer R. Management of the adverse effects of antiretroviral therapy and medication adherence. Clinical Infectious Diseases 2000:S96-S116.
25. Chesney M. Factors affecting adherence to antiretroviral therapy. Clinical Infectious Diseases 2000; 30(Suppl. 2):S171-S176.
26. Holzemer W, Corless I, Nokes K, Turner J, Brown M, Powell-Cope G, Inouve J, Henry S, Nicholas P and Portillo C. Predictors of self-reported adherence in persons living with HIV disease. AIDS Patient Care and STDs 1999; 13:185-97
27. Eron J, Yetzer E, Ruane P, Becker S, Sawyerr G, Fisher R, Tolson J and Shaefer M. Efficacy, safety, and adherence with a twice-daily combination lamivudine/zidovudine tablet formulation, plus a protease inhibitor, in HIV infection. AIDS 2000; 14:671-681.
28. Mehta S, Moore R and Graham N. Potential factors affecting adherence with HIV theory. AIDS 1997; 11:1665-1670.
29. Miller N. Compliance with treatment regimens in chronic asymptomatic diseases. Americal Journal of Medicine 1997; 17:43-49
30. Kuritzkes D, Bassett R and Johnson V. Continued lamivudine versus delavirdine in combination with indinavir and zidovudine or stavudine in lamivudine-experienced patients. AIDS 2000; 14:1553-1561.
31. Ellis S, Shumaker S, Seiber W and Rand C. Adherence to Pharmacological interventions: current trends and future irections. Controlled Clinical Trials 2000; 21:218S-225S.
32. Kuritzkes D, Bassett R, Johnson V, Marschner I, Eron J, Sommadossi J, Acosta E, Murphy R, Fife K, Wood K, Bell D, Martinez A and Pettinelli C. Lamivudine in combination with zidovudine, stavudine, or didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial. AIDS 1999; 13:685-694.
33. Chesney M, Ickovics J, Chambers D, Gifford A, Neidig J, Zwickl B and Wu A. Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: the AACTG adherence instrument. AIDS Care 2000; 12:255-266.
34. Tuldra A, Fumaz CR, Ferrer MJ, Bayes R, Arno A, Balague M, Bonjoch A, Jou A, Negredo E, Parades R, Ruiz L, Romeu J, Sierra G, Tural C, Burger D and Clotet B. Prospective randomized two-arm controlled study to determine the efficacy of a specific intervention to improve long-term adherence to highly active antiretroviral therapy. Journal of Acquired Immune Deficiency Syndrome 2000; 25:221-228.
35. Mirosky J and Ross C. Age and depression. Journal of Health and Social Behavior 1992; 33:187-205.
36. Radloff L. The CES-D scale: a self-report depression scale for research in the general population. Applied Psychological Measures 1977; 1:385-401.
37. Cohen S, Kessler RC and Gordon LU. Measuring stress: a guide for health and social scientists. 1995. New York: Oxford University Press.
38. Zeger SL and Liang KY. Longitudinal data analysis for discrete and continuous outcomes. Biometrics 1986; 42:121-130.
39. Havlir DV, Bassett R, Levitan D, Gilbert P, Tebas P, Collier AC, Hirsch MS, Ignacio C, Condra J, Gunthard HF, Richman DD and Wong JK. Prevalence and predictive value of intermittent viremia with combination HIV therapy. Journal of the American Medical Association 2001; 286:171-179.
40. Duran S, Spire B, Raffi F, Walter V, Bouhour D, Journot V, Cailleton V, Leport C and Moatti JP. Self-reported symptoms after initiation of a protease inhibitor in HIV-infected patients and their impact on adherence to HAART. HIV Clinical Trials 2000; 12:38-45.
41. Samet JH, Sullivan LM, Traphagen ET and Ickovics JR. Measuring adherence among HIV-infected persons: is MEMS consummate technology. AIDS and Behavior 2001; 5:21-29.
42. Friedman L, Furburg C and DeMets D. Fundamentals of clinical trials. 3rd edition, 1996. St. Louis: Mosby.
43. Ickovics JR and Meade C. Adherence to HAART among patients with HIV: breakthroughs and barriers. AIDS Clinical Care (in press).